Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M. Sikov, Hope S. Rugo, Mark D. McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag, Danielle Sullivan, Norman Wolmark, Kristi McIntyre, Jose J. Ponce Lorenzo, Otto Metzger Filho, Priya Rastogi, W. Fraser Symmans, Xuan Liu, Charles E. Geyer

Research output: Contribution to journalArticlepeer-review

387 Scopus citations

Fingerprint

Dive into the research topics of 'Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences